Format

Send to

Choose Destination
See comment in PubMed Commons below
Gastroenterol Hepatol. 2017 Sep 2. pii: S0210-5705(17)30183-8. doi: 10.1016/j.gastrohep.2017.07.006. [Epub ahead of print]

New therapeutic perspectives in non-alcoholic steatohepatitis.

[Article in English, Spanish]

Author information

1
Unidad Aparato Digestivo, CIBERehd, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, España.
2
Hospital Universitario Virgen de la Macarena, Sevilla, España.
3
Unidad Aparato Digestivo, CIBERehd, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, España. Electronic address: mromerogomez@us.es.

Abstract

Management of non-alcoholic steatohepatitis is focused on restitution of metabolic derangement, weight loss and drugs able to improve steatosis, ballooning and fibrosis. Life-style interventions based on Mediterranean diet and increasing physical activity are the first line therapy. In patients with unsuccessful life-style intervention several drugs are under development: agonist PPAR, agonist GLP-1R and agonist FXR together with drugs focussing on inflammation, ballooning, apoptosis and fibrosis. Bariatric surgery or advanced endoscopy are reserved for morbid obese without response to life-style intervention and weighting loss drugs.

KEYWORDS:

Agonistas glucagon-like peptide-1 receptor; Body mass index; Glucagon-like peptide-1 receptor agonists; Obesidad visceral; Obeticolic acid; Peroxisome proliferator-activated receptor; Peroxisome proliferator-activated receptors; Visceral obesity; Ácido obeticólico; Índice de masa corporal

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ediciones Doyma, S.L.
    Loading ...
    Support Center